在心力衰竭中改变血液动力学和末端器官损伤:对肺和的影响
Frederik H Verbrugge1,2, Marco Guazzi3, Jeffrey M Testani4
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (F.H.V., B.A.B.).
Circulation
|September 8, 2020
概括
心脏衰竭涉及异常的血液流动, 了解这些血液动力学变化是开发心力衰竭患者更好的治疗方法的关键.
科学领域:
- 心脏病学
- 生理学
背景情况:
- 心脏衰竭呈现出异常的血液动力学,包括高心脏填充压力 (向后衰竭) 和/ 或低心脏输出 (向前衰竭).
- 这些血液动力学障碍在压力 (例如运动) 中表现出,即使在静止状态下正常,也会影响多个器官系统.
- 超出心肌细胞的因素,如心周约束和心室相互作用,影响心力衰竭的血液动力学.
研究的目的:
- 阐明心力衰竭中血液动力学障碍的机制.
- 探索这些血液动力学变化对肺和功能的影响.
- 确定新的治疗策略的潜在目标.
主要方法:
- 这项研究回顾了有关心力衰竭病理生理学和血液动力学的现有文献.
- 它分析了血液动力学改变对肺和系统的影响.
- 该审查考虑了各种心力衰竭表型,包括减少和保留的喷射分数.
主要成果:
- 心力衰竭的血液动力异常会导致肺部问题,如血栓塞和血管疾病.
- 在脏中,这些干扰会导致/水的保留和功能障碍.
- 这些效应在各种心力衰竭表现中观察到,从急性到慢性,以及冲击到保存的输液.
结论:
- 在心力衰竭中,血液动力学变化显著影响肺和功能.
- 更深入地了解这些机制对于改善患者的结果至关重要.
- 针对血液动力学障碍的新型策略可能会带来治疗效益.
相关概念视频
Heart Failure II: Pathophysiology
517
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
517
Heart Failure Drugs: Diuretics
674
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
674
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
737
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
737
Heart Failure III: Clinical Manifestations
335
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
335
Pathophysiology of Heart Failure
2.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.4K
Heart Failure I: Introduction
555
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
555


